About Espee Therapeutics LLP
Data last updated:
Espee Therapeutics LLP is a limited liability partnership (LLP) based in Ahmedabad, Gujarat, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 25 November 2016 and has been in existence for over 10 years.
The LLP is registered with the Registrar of Companies (ROC), Ahmedabad, under LLPIN AAH-8938. Its GSTIN is 24AAGFE1071K1ZM (Gujarat).
The LLP has a total obligation of contribution of ₹1 Cr. It is led by designated partners Swapnil Jatinbhai Shah and Anar Swapnil Shah.
Its latest statement of accounts is for the year ended 31 March 2025. The registered office is at Jayantilal Park, Ahmedabad, Gujarat.
As per the financials filed for FY 2021, the LLP reported a revenue of ₹13.65 Cr, a growth of 80% compared to the previous year. For the same year it recorded a net profit of ₹3.78 Cr (net margin 27.7%) and EBITDA of ₹13.99 Cr (EBITDA margin 102.4%). Revenue has grown at a compounded annual rate (CAGR) of 57% over three years.
The LLP has about 11 employees on its provident fund (EPFO) records.
As per MCA filings, the LLP has open charges of ₹1.07 Cr and satisfied charges of ₹10.24 Cr on record. Court records list 1 case involving the LLP, including 1 filed against it.
For more details, the LLP can be reached via its website espeelife.com.
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered AddressS.T. 1101 One 42 B/H. Ashok Vatika Nr. Jayantilal Park Brts Ambli Bopal Ro, Ad, Ahmedabad, Gujarat, India – 380054
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Financials of Espee Therapeutics LLP FY 2025 filings available
Espee Therapeutics LLP reported revenue of ₹13.65 Cr (up 80% YoY) for FY 2021.
Compounded Annual Growth Rate (CAGR) of Espee Therapeutics LLP
Revenue has grown at a compounded annual rate (CAGR) of 57% over three years, including 80% growth in the latest year. EBITDA rose 95% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Espee Therapeutics LLP
| Statement of Account and Solvency | FY 2020-21 | FY 2019-20 | FY 2018-19 | FY 2017-18 | FY 2016-17 |
|---|---|---|---|---|---|
| Income and Expenditure | |||||
| Turnover | ₹13.65 Cr | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Income | •••• | •••• | •••• | •••• | •••• |
| Purchases and Direct Costs | •••• | •••• | •••• | •••• | •••• |
| Personnel Expenses | •••• | •••• | •••• | •••• | •••• |
| Administrative Expenses | •••• | •••• | •••• | •••• | •••• |
| Interest | •••• | •••• | •••• | •••• | •••• |
| Depreciation | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax | •••• | •••• | •••• | •••• | •••• |
| Profit After Tax | ₹3.78 Cr | •••• | •••• | •••• | •••• |
| Profit Transferred to Partners | •••• | •••• | •••• | •••• | •••• |
| Assets and Liabilities | |||||
| Partners' Contribution | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Secured Loans | •••• | •••• | •••• | •••• | •••• |
| Unsecured Loans | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Other Liabilities and Provisions | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Loans and Advances | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Espee Therapeutics LLP
| Statement of Account and Solvency | FY 2020-21 | FY 2019-20 | FY 2018-19 | FY 2017-18 | FY 2016-17 |
|---|---|---|---|---|---|
| Profitability | |||||
| Net Profit Margin | 27.7% | •••• | •••• | •••• | •••• |
| Return on Partners' Funds | •••• | •••• | •••• | •••• | •••• |
| Return on Assets | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt to Partners' Funds | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Turnover Growth | •••• | •••• | •••• | •••• | •••• |
| Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form 8. The full year-wise statements and ratios of Espee Therapeutics are in the company report.
Financial statements from FY 2017
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Auditor Details of Espee Therapeutics LLP
Espee Therapeutics LLP is audited by PARIKH & MAJMUDAR for the financial year 2021.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| PARIKH & MAJMUDAR | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Designated Partners of Espee Therapeutics LLP
Espee Therapeutics has 2 designated partners on record. No former designated partners are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Swapnil Jatinbhai Shah Also directs: Aelius Projects LLP, Remus Pharmaceuticals Limited, Senores Pharmaceuticals Limited and 4 more | Designated Partner | 25 Nov 2016 | 9 Years 10 Months | Current |
| Anar Swapnil Shah Also directs: Aelius Projects LLP, Remus Pharmaceuticals Limited, Senores Biologics Private Limited and 5 more | Designated Partner | 25 Nov 2016 | 9 Years 10 Months | Current |
Ownership and Shareholding of Espee Therapeutics LLP
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Espee Therapeutics LLP
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Nov 2025 | Hdfc Bank Limited | ₹32.08 Lakh | Open |
| 06 May 2024 | Hdfc Bank Limited | ₹20 Lakh | Open |
| 16 Nov 2023 | Hdfc Bank Limited | ₹55 Lakh | Open |
| 05 Apr 2023 | Icici Bank Limited | ₹2.45 Cr | Satisfied |
| 15 Jan 2021 | Icici Bank Limited | ₹7.79 Cr | Satisfied |
Total charge records: 5 View all charges
Legal Cases of Espee Therapeutics LLP
Espee Therapeutics LLP has 1 court case on record: 1 filed against it. All case is disposed. Status as checked on 21 Sep 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 1 | 1 | 0 |
Cases on record (1 of 1)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Ahmedabad, Gujarat | Criminal complaint | Filed against the company by Government of Gujarat | Disposed |
Full case history
All 1 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Employees and EPFO Compliance at Espee Therapeutics LLP
Espee Therapeutics LLP has a workforce of 15 employees as of Mar 27, 2024.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Espee Therapeutics LLP
Espee Therapeutics LLP has 2 designated partner changes on record since 2016: 2 appointments. The latest: Anar Swapnil Shah was appointed as Designated Partner on 25 Nov 2016.
1 earlier event is listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Espee Therapeutics LLP
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Espee Therapeutics LLP
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Espee Therapeutics LLP
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Espee Therapeutics LLP
Espee Therapeutics has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AAGFE1071K1ZM | Gujarat | Active | 12 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Espee Therapeutics LLP
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Espee Therapeutics LLP
Espee Therapeutics is an active limited liability partnership based in Ahmedabad, Gujarat, India. The LLP works in drug formulation and development, within the pharma industry. It was incorporated on 25 November 2016 (10+ years old) and is registered under LLPIN AAH-8938.
Espee Therapeutics reported revenue of ₹13.65 Cr for FY 2021 (up 80% YoY).
Espee Therapeutics has 2 current designated partners:
- Swapnil Jatinbhai Shah - Designated Partner
- Anar Swapnil Shah - Designated Partner
Espee Therapeutics reported a net profit of ₹3.78 Cr (net margin 27.7%) and EBITDA of ₹13.99 Cr (EBITDA margin 102.4%) for FY 2021, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Espee Therapeutics is 57% over three years. In the latest year (FY 2021) revenue rose 80%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Espee Therapeutics is 24AAGFE1071K1ZM, registered in Gujarat.
The LLPIN (Limited Liability Partnership Identification Number) of Espee Therapeutics is AAH-8938. It is issued by the Ministry of Corporate Affairs and uniquely identifies the LLP in India.
Espee Therapeutics has 1 court case on record: 1 filed against it.
Espee Therapeutics was incorporated on 25 November 2016, making it 10+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Anar Swapnil Shah was appointed as Designated Partner on 25 Nov 2016. Swapnil Jatinbhai Shah was appointed as Designated Partner on 25 Nov 2016.